{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:55:54Z","timestamp":1791136554301,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T00:00:00Z","timestamp":1239840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T00:00:00Z","timestamp":1239840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1038\/leu.2009.69","type":"journal-article","created":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T09:42:27Z","timestamp":1239874947000},"page":"1614-1621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL"],"prefix":"10.1038","volume":"23","author":[{"given":"A A","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sch\u00fcll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Oancea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hundertmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O G","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ruthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,16]]},"reference":[{"key":"BFleu200969_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164\u2013172.","journal-title":"N Engl J Med"},{"key":"BFleu200969_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079\u20131082.","journal-title":"Science"},{"key":"BFleu200969_CR3","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MW Deininger","year":"1997","unstructured":"Deininger MW, Goldman JM, Lydon N, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691\u20133698.","journal-title":"Blood"},{"key":"BFleu200969_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFleu200969_CR5","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498\u20133505.","journal-title":"Blood"},{"key":"BFleu200969_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","volume":"13","author":"P Ramirez","year":"2008","unstructured":"Ramirez P, DiPersio JF . Therapy options in imatinib failures. Oncologist 2008; 13: 424\u2013434.","journal-title":"Oncologist"},{"key":"BFleu200969_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1389557043487321","volume":"4","author":"SW Cowan-Jacob","year":"2004","unstructured":"Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004; 4: 285\u2013299.","journal-title":"Mini Rev Med Chem"},{"key":"BFleu200969_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.6004\/jnccn.2005.0045","volume":"3","author":"M Deininger","year":"2005","unstructured":"Deininger M . Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005; 3: 757\u2013768.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFleu200969_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117\u2013125.","journal-title":"Cancer Cell"},{"key":"BFleu200969_CR10","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ . Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808\u20134817.","journal-title":"Blood"},{"key":"BFleu200969_CR11","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1182\/blood-2003-03-0811","volume":"102","author":"T Beissert","year":"2003","unstructured":"Beissert T, Puccetti E, Bianchini A, G\u00fcller S, Boehrer S, Hoelzer D et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003; 102: 2985\u20132993.","journal-title":"Blood"},{"key":"BFleu200969_CR12","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/ijc.23467","volume":"122","author":"T Beissert","year":"2008","unstructured":"Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C et al. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR\/ABL. Int J Cancer 2008; 122: 2744\u20132752.","journal-title":"Int J Cancer"},{"key":"BFleu200969_CR13","first-page":"3409","volume":"60","author":"E Puccetti","year":"2000","unstructured":"Puccetti E, G\u00fcller S, Orleth A, Br\u00fcggenolte N, Hoelzer D, Ottmann OG et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000; 60: 3409\u20133413.","journal-title":"Cancer Res"},{"key":"BFleu200969_CR14","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082\u20136093.","journal-title":"Mol Cell Biol"},{"key":"BFleu200969_CR15","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2003-09-3335","volume":"103","author":"X Zheng","year":"2004","unstructured":"Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103: 3535\u20133543.","journal-title":"Blood"},{"key":"BFleu200969_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/ng0398-280","volume":"18","author":"D Baril\u00e1","year":"1998","unstructured":"Baril\u00e1 D, Superti-Furga G . An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 1998; 18: 280\u2013282.","journal-title":"Nat Genet"},{"key":"BFleu200969_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/j.1460-2075.1989.tb03358.x","volume":"8","author":"WM Franz","year":"1989","unstructured":"Franz WM, Berger P, Wang JY . Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J 1989; 8: 137\u2013147.","journal-title":"EMBO J"},{"key":"BFleu200969_CR18","first-page":"2343","volume":"61","author":"E Laurent","year":"2001","unstructured":"Laurent E, Talpaz M, Kantarjian H, Kurzrock R . The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001; 61: 2343\u20132355.","journal-title":"Cancer Res"},{"key":"BFleu200969_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ . Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 1109\u20131118.","journal-title":"Nat Struct Mol Biol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu200969.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200969","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200969.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:49:47Z","timestamp":1648730987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu200969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,16]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["BFleu200969"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.69","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,16]]},"assertion":[{"value":"22 December 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}